Search clinical trials for: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics

Total 2333 results

Yonsei University

Active, not recruiting

Effect of Mirabegron on Bladder Compliance

Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics

Korea, Republic of
Aaron Cypess
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Obesity

United States
The Affiliated Ganzhou Hospital of Nanchang University

Active, not recruiting

Acupuncture Combined With Mirabegron in the Treatment of OAB (ACWMITTOOAB)

Overactive Bladder

China
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Astellas Pharma Inc

Completed

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

Healthy Subjects | Bioavailability | Pharmacokinetics of Mirabegron

Netherlands
Thomas Jefferson University
Astellas Pharma Inc

Terminated

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Achalasia

United States
Peking Union Medical College Hospital

Not yet recruiting

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

Overactive Bladder
Cedars-Sinai Medical Center

Recruiting

Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)

Syncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic Intolerance

United States
Far Eastern Memorial Hospital

Recruiting

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Overactive Bladder Syndrome

Taiwan
Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
Henning Bundgaard

Completed

Beta 3 Agonist Treatment in Heart Failure (Beat-HF)

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Australia, Denmark
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Seoul National University Hospital

Unknown

MIrabegron With oveRACtive bLadder Symptoms in mEn

Overactive Bladder

Korea, Republic of
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Samsung Medical Center

Completed

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Overactive Bladder

Korea, Republic of
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Astellas Pharma Inc

Completed

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Healthy Subjects | Pharmacokinetics

Netherlands
Astellas Pharma Inc

Completed

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Overactive Bladder | Pharmacokinetics

France
Far Eastern Memorial Hospital

Recruiting

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Female Patients With Overactive Bladder Syndrome

Taiwan
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
Tianjin Medical University General Hospital

Recruiting

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Intracerebral Haemorrhage

China
University Hospitals Cleveland Medical Center

Withdrawn

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

Overactive Bladder

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
University of Alabama at Birmingham

Completed

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) (PTNS-M)

Overactive Bladder

United States
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Metabolic Processes

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Catalan Institute of Health

Completed

Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron

Overactive Bladder Syndrome
Shachi Tyagi
National Institute on Aging (NIA)

Recruiting

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women (SLAB)

Nocturia | Urgency Urinary Incontinence

United States
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Brown Fat Activation Study

Metabolic Syndrome | Obese

United States
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
Unity Health Toronto
Canadian Urological Association

Unknown

Mirabegron And Ureteral Stent-related Pain (MAP) Trial (MAP)

Nephrolithiasis

Canada
Baylor Research Institute
The Methodist Hospital Research Institute; International Urogynecological Association

Completed

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Overactive Bladder | Lower Urinary Tract Symptoms | Dementia | Incontinence, Urge

United States
Chang Gung Memorial Hospital

Completed

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

Urinary Bladder, Overactive | Sexual Behavior | Sexual Function Disturbances | Behavior Therapy | Sexual Activity

Taiwan
University Hospital, Basel, Switzerland

Completed

Beta 2 Adrenergic Stimulation vs Cold Exposure to Activate Human Brown Adipose Tissue (ASCENT)

Thermogenesis

Switzerland
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8577 in Patients With Overactive Bladder

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously

Healthy Volunteers | Pharmacokinetics of Mirabegron

France
Mansoura University

Recruiting

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Voiding Disorders

Egypt

3

Subscribe